PTEN and melanoma: PTEN loss, which activates the PI3K/AKT pathway, induces PD-1 and PD-L1 inhibitor-resistance by promoting the release of anti-inflammatory cytokines that reduce infiltration and activation of CD8+ cytotoxic T cells in melanoma patients (36).